Skip to main content
驱动力 logo

驱动力 — Investor Relations & Filings

Ticker · 920275 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 479 across all filing types
Latest filing 2024-04-28 Annual Report
Country CN China
Listing Beijing Stock Exchange 920275

About 驱动力

https://www.chinaedrive.com/

Drive Power Bio-tech specializes in the research, development, and manufacturing of functional additives designed for animal nutrition. The company focuses on hematopoietic technology, providing solutions that enhance hemoglobin synthesis, strengthen immune responses, and support intestinal health. Its product portfolio includes specialized nutritional supplements that optimize metabolic processes and improve growth performance. By leveraging biotechnological innovation, the company develops high-efficiency additives aimed at enhancing physiological health and production efficiency in large-scale agricultural environments.

Recent filings

Filing Released Lang Actions
2022年年度报告（更正后）
Annual Report Classification · 100% confidence The document is titled '年度报告' which translates to 'Annual Report' and covers the fiscal year 2022. It includes detailed sections such as company overview, financial data and indicators, management discussion and analysis, major events, shareholder information, financing and profit distribution, board and senior management details, industry information, corporate governance, internal controls, and financial accounting reports. The document contains comprehensive financial statements, management analysis, and audited financial data with a standard unqualified audit opinion from a certified accounting firm. The length of the document (15,000 characters) and the depth of content confirm it is the full annual report rather than an announcement or summary. Therefore, the appropriate classification is Annual Report (10-K). FY 2022
2024-04-28 Chinese
前期会计差错更正公告
Audit Report / Information Classification · 95% confidence The document is a detailed announcement regarding the correction of prior period accounting errors by Guangdong Drive Biological Technology Group Co., Ltd. It references specific accounting standards (Accounting Standard No. 28), regulatory disclosure rules from the China Securities Regulatory Commission, and includes detailed retrospective adjustments to financial data for multiple periods (2021, 2022, and quarterly periods in 2023). It also includes opinions from the board, supervisory board, audit committee, and an accounting firm’s assurance report. The document is not a full annual or interim report but a standalone correction announcement with detailed financial impact data and audit opinions. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit-related disclosure about accounting policy changes and error corrections, not a full annual or quarterly report. The document length (6219 characters) and content confirm it is not a brief announcement or a report publication notice, but a substantive audit-related disclosure. 9M 2023
2024-04-28 Chinese
关于召开2023年年度股东大会通知公告
AGM Information Classification · 100% confidence The document is a notice announcing the convening of the 2023 Annual General Meeting (AGM) of Guangdong Drive Biological Technology Group Co., Ltd. It details the meeting date, voting methods, agenda items to be discussed, and procedural information for shareholders. It references the 2023 Annual Report and other reports that have been published separately on the official exchange platform, but does not contain the reports themselves. The document is relatively short (3548 characters) and serves as an announcement for the AGM rather than the report or results of the meeting. Therefore, it fits the category of AGM Information (AGM-R).
2024-04-28 Chinese
关于注销2022年股权激励计划第二期及离退人员股票期权的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Guangdong Drive Biological Technology Group Co., Ltd. regarding the cancellation of stock options under its 2022 equity incentive plan. It details the board and supervisory approvals, legal opinions, and the reasons for the cancellation of unexercised stock options. The content focuses on corporate governance and equity incentive plan adjustments rather than financial results or earnings. It is not a full financial report, earnings release, or audit report. It is also not a proxy solicitation or voting results announcement. The document is a regulatory announcement about changes in the company's equity incentive plan, specifically the cancellation of stock options, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories like Capital/Financing Update or Director's Dealing. The document length is 4206 characters, which is relatively short but contains substantive information about the cancellation of stock options and related approvals, not just a brief notice or report publication announcement.
2024-04-28 Chinese
2023年度报告说明会预告公告
Investor Presentation Classification · 90% confidence The document is a notice announcing a scheduled investor presentation related to the company's 2023 Annual Report. It explicitly states that the 2023 Annual Report was disclosed earlier (announcement number 2024-012) and that this document is to inform investors about the upcoming performance explanation meeting (业绩说明会) to be held remotely. The document is short (824 characters) and serves as an announcement of the event rather than containing the actual report or detailed financial data. Therefore, it fits the category of an Investor Presentation announcement or notice. Given the options, the best fit is 'Investor Presentation' (IP) as it is a detailed presentation for investors focusing on financials, strategy, and market position, even though this document is a notice about the presentation rather than the presentation itself. However, since the document is primarily an announcement of the meeting and not the presentation materials themselves, and considering the 'Menu vs Meal' rule, it is more appropriate to classify this as a Report Publication Announcement (RPA) or Regulatory Filing (RNS). But since the document is specifically about an investor presentation meeting, the closest specific category is Investor Presentation (IP). Confidence is high due to explicit mention of the investor meeting related to the annual report.
2024-04-28 Chinese
募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集资金存放与实际使用情况的专项报告" which translates to a "Special Report on the Deposit and Actual Use of Raised Funds." It details the company's fundraising activities, including the amount raised, usage of funds, management of funds, and related audit and verification opinions. It references regulatory approvals from the China Securities Regulatory Commission and includes detailed financial figures on the use of raised capital. The document is a comprehensive report on the use and management of capital raised through a public stock issuance, not merely an announcement or a brief summary. It is not an annual or interim financial report, nor is it a proxy, governance, or legal filing. The content fits the category of a Capital/Financing Update as it focuses on fundraising, capital usage, and related financial management.
2024-04-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.